SVB Leerink Upgrades Reata Pharmaceuticals to Outperform, Raises Price Target to $115
Portfolio Pulse from richadhand@benzinga.com
SVB Leerink analyst Joseph Schwartz upgraded Reata Pharmaceuticals (NASDAQ:RETA) from Market Perform to Outperform and raised the price target from $80 to $115.
June 12, 2023 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reata Pharmaceuticals upgraded to Outperform by SVB Leerink, with a raised price target of $115.
The upgrade from Market Perform to Outperform and the raised price target from $80 to $115 by SVB Leerink analyst Joseph Schwartz indicate a positive outlook for Reata Pharmaceuticals. This news is likely to have a positive short-term impact on the stock price as it reflects increased confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100